Enovis (ENOV) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
6 Apr, 2026Executive summary
Annual meeting scheduled for May 19, 2026, to be held virtually for shareholder participation.
Shareholders are encouraged to review proxy materials online or request copies before voting.
Voting matters and shareholder proposals
Election of ten directors is proposed, with all nominees recommended for approval.
Ratification of Ernst & Young LLP as independent auditor for fiscal year ending December 31, 2026.
Advisory vote on executive compensation (say-on-pay) is included.
Amendment to the 2020 Omnibus Incentive Plan is up for approval.
Proxies are authorized to vote on other business as may arise at the meeting.
Board of directors and corporate governance
Ten director nominees are listed for election, reflecting board continuity and governance focus.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Enovis
- Board recommends all proposals, emphasizing governance, pay-for-performance, and ESG focus.ENOV
Proxy filing6 Apr 2026 - Double-digit growth, tech innovation, and ASC expansion fuel strong outlook for 2026.ENOV
2026 CG Musculoskeletal Conference4 Mar 2026 - 2025 saw robust sales growth, margin gains, and innovation, with 2026 guidance targeting further improvements.ENOV
Q4 202526 Feb 2026 - Lima integration and new product launches drive growth, margin expansion, and innovation in 2025.ENOV
CG 2025 Musculoskeletal Conference13 Feb 2026 - Q2 sales up 23%, margin expansion, and Lima integration ahead of plan with raised EPS guidance.ENOV
Q2 20242 Feb 2026 - Integration and portfolio expansion drive growth, margin gains, and strong outlook into 2025.ENOV
Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 20242 Feb 2026 - Lima acquisition and innovation drive 2024 growth, margin gains, and integration progress.ENOV
The 44th Annual William Blair Growth Stock Conference31 Jan 2026 - 2024 growth guided at 5%-6% with margin expansion as integration headwinds ease.ENOV
2024 Wells Fargo Healthcare Conference22 Jan 2026 - Q3 sales up 21% and adjusted EPS up 30%, led by Reconstructive and Lima integration.ENOV
Q3 202416 Jan 2026